| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Norditropin Human Growth Hormone Launched in the U.S. NEW YORK-- Feb. 20, 1997-- Norditropin(R) (somatropin (rDNA origin) for injection), indicated for the long-term treatment of children who have growth failure due to inadequate secretion of endogenous (pituitary gland produced) growth hormone is now available in the U.S. Lars Barfod, vice president, marketing and business development, Novo Nordisk Pharmaceuticals Inc., said, "We are pleased to introduce Norditropin(R) to the U.S. market. Norditropin(R) has been available in 66 countries worldwide since 1988, and has been used with success by more than 30,000 children." He added, "This product launch marks another goal reached by Novo Nordisk in our dedication and commitment to serving the needs of those with endocrine disorders in the US." Wayman Wendell Cheatham, MD, medical director, Novo Nordisk Pharmaceuticals Inc., said, "Human growth hormone is responsible for stimulating normal skeletal, connective tissue, muscle and organ growth in children and adolescents. It is also active in normal protein, carbohydrate and fat metabolism." He added, "If the amount of growth hormone production by the body is insufficient, short stature, reduced muscle and soft tissue mass and altered nutrient metabolism result. Such problems significantly impact an individual's physical function throughout life, if not treated appropriately. Therapy with Norditropin(R) around the world has been highly successful in reducing such effects in children and adolescents diagnosed with growth hormone insufficiency by maintaining appropriate growth and development to maturity." Novo Nordisk A/S is the world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore, the company is the world's largest producer of industrial enzymes.
|